COMPLEMENT INHIBITOR ECULIZUMAB IN ATYPICAL HEMOLYTIC-UREMIC SYNDROME:
SINGLE CENTER CASE SERIES
- Monika Vitkauskaitė
, - Artūras Vinikovas,
- Marius Miglinas,
- Laurynas Rimševičius,
- Agnė Čerkauskaitė,
- Ernesta Mačionienė,
- Eglė Ašakienė
Monika Vitkauskaitė
Vilniaus universitetas Medicinos fakultetas
Corresponding Author:vitkausk.monika@gmail.com
Author ProfileArtūras Vinikovas
Vilniaus universitetas Medicinos fakultetas
Author ProfileMarius Miglinas
Vilniaus universitetas Medicinos fakultetas
Author ProfileLaurynas Rimševičius
Vilniaus universitetas Medicinos fakultetas
Author ProfileAgnė Čerkauskaitė
Vilniaus universitetas Medicinos fakultetas
Author ProfileErnesta Mačionienė
Vilniaus universitetas Medicinos fakultetas
Author ProfileEglė Ašakienė
Vilniaus universitetas Medicinos fakultetas
Author ProfileAbstract
Our case series showed that eculizumab is efficacious and safe in
treating atypical hemolytic-uremic syndrome, as well as it has positive
effects on quality of life. Further extensive studies are required to
develop unified treatment guidelines.24 Sep 2021Submitted to Clinical Case Reports 25 Sep 2021Submission Checks Completed
25 Sep 2021Assigned to Editor
04 Oct 2021Reviewer(s) Assigned
17 Nov 2021Review(s) Completed, Editorial Evaluation Pending
17 Nov 2021Editorial Decision: Revise Minor
16 Jan 20221st Revision Received
17 Jan 2022Submission Checks Completed
17 Jan 2022Assigned to Editor
17 Jan 2022Review(s) Completed, Editorial Evaluation Pending
16 Feb 2022Editorial Decision: Accept
